CN1827599A - 盐酸伊伐布雷定的βd-晶形、其制备方法和含有它的药物组合物 - Google Patents
盐酸伊伐布雷定的βd-晶形、其制备方法和含有它的药物组合物 Download PDFInfo
- Publication number
- CN1827599A CN1827599A CNA2006100580746A CN200610058074A CN1827599A CN 1827599 A CN1827599 A CN 1827599A CN A2006100580746 A CNA2006100580746 A CN A2006100580746A CN 200610058074 A CN200610058074 A CN 200610058074A CN 1827599 A CN1827599 A CN 1827599A
- Authority
- CN
- China
- Prior art keywords
- hydrochloric acid
- crystalline form
- acid ivabradine
- ivabradine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
- ACRHBAYQBXXRTO-OAQYLSRUSA-N ivabradine Chemical compound C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 ACRHBAYQBXXRTO-OAQYLSRUSA-N 0.000 title claims description 27
- 229960003825 ivabradine Drugs 0.000 title claims description 22
- 238000002360 preparation method Methods 0.000 title claims description 10
- 238000000034 method Methods 0.000 title claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 44
- 230000003595 spectral effect Effects 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000002425 crystallisation Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000001228 spectrum Methods 0.000 claims description 4
- 230000008025 crystallization Effects 0.000 claims description 3
- 230000018044 dehydration Effects 0.000 claims description 3
- 238000006297 dehydration reaction Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 2
- 230000000059 bradycardiac effect Effects 0.000 claims description 2
- 239000013078 crystal Substances 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims 1
- 229960000504 ivabradine hydrochloride Drugs 0.000 abstract description 2
- HLUKNZUABFFNQS-ZMBIFBSDSA-N ivabradine hydrochloride Chemical compound Cl.C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 HLUKNZUABFFNQS-ZMBIFBSDSA-N 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 description 4
- 238000000634 powder X-ray diffraction Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- -1 creme Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
- B01J23/48—Silver or gold
- B01J23/50—Silver
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
- B01J23/54—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals combined with metals, oxides or hydroxides provided for in groups B01J23/02 - B01J23/36
- B01J23/56—Platinum group metals
- B01J23/62—Platinum group metals with gallium, indium, thallium, germanium, tin or lead
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
- B01J23/54—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals combined with metals, oxides or hydroxides provided for in groups B01J23/02 - B01J23/36
- B01J23/56—Platinum group metals
- B01J23/62—Platinum group metals with gallium, indium, thallium, germanium, tin or lead
- B01J23/622—Platinum group metals with gallium, indium, thallium, germanium, tin or lead with germanium, tin or lead
- B01J23/626—Platinum group metals with gallium, indium, thallium, germanium, tin or lead with germanium, tin or lead with tin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/70—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper
- B01J23/89—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper combined with noble metals
- B01J23/892—Nickel and noble metals
-
- B01J35/23—
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
- B01J37/02—Impregnation, coating or precipitation
- B01J37/0201—Impregnation
- B01J37/0211—Impregnation using a colloidal suspension
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
- B01J37/02—Impregnation, coating or precipitation
- B01J37/0201—Impregnation
- B01J37/0213—Preparation of the impregnating solution
-
- C—CHEMISTRY; METALLURGY
- C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
- C10G—CRACKING HYDROCARBON OILS; PRODUCTION OF LIQUID HYDROCARBON MIXTURES, e.g. BY DESTRUCTIVE HYDROGENATION, OLIGOMERISATION, POLYMERISATION; RECOVERY OF HYDROCARBON OILS FROM OIL-SHALE, OIL-SAND, OR GASES; REFINING MIXTURES MAINLY CONSISTING OF HYDROCARBONS; REFORMING OF NAPHTHA; MINERAL WAXES
- C10G45/00—Refining of hydrocarbon oils using hydrogen or hydrogen-generating compounds
- C10G45/32—Selective hydrogenation of the diolefin or acetylene compounds
- C10G45/34—Selective hydrogenation of the diolefin or acetylene compounds characterised by the catalyst used
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
- B01J21/02—Boron or aluminium; Oxides or hydroxides thereof
- B01J21/04—Alumina
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
- B01J23/54—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals combined with metals, oxides or hydroxides provided for in groups B01J23/02 - B01J23/36
- B01J23/56—Platinum group metals
- B01J23/62—Platinum group metals with gallium, indium, thallium, germanium, tin or lead
- B01J23/622—Platinum group metals with gallium, indium, thallium, germanium, tin or lead with germanium, tin or lead
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/70—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper
- B01J23/89—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper combined with noble metals
- B01J23/8926—Copper and noble metals
-
- B01J35/393—
-
- B01J35/397—
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
通式(I)的盐酸伊伐布雷定的βd-晶形,其特征在于其粉末X射线衍射图。药物。
Description
本发明涉及通式(I)的盐酸伊伐布雷定(ivabradine hydrochloride)的新βd-晶形、其制备方法和含有它的药物组合物:
伊伐布雷定及其与药学上可接受的酸形成的加成盐、更具体为其盐酸盐具有极为有价值的药理和治疗特性,尤其是减慢心律(bradycardic)特性,从而使得这些化合物可用于治疗或预防心肌缺血的各种临床情况如心绞痛、心肌梗死和相关节律失常,以及涉及节律失常的各种病理情况、尤其是室上性节律失常,和心力衰竭。
欧洲专利说明书EP 0534 859中已经描述了伊伐布雷定及其与药学上可接受的酸形成的加成盐、更尤其是其盐酸盐的制备和治疗用途。
鉴于该化合物的药物价值,所以最重要的是获得具有极佳纯度的该化合物。另外重要的是能够通过一种易于转化成工业化规模的方法合成它,尤其是允许快速过滤和干燥的形式。最终,该晶形必须完全可再现、易于配制且足够稳定以便其长期贮存,而对温度、光或氧的水平没有特定的要求。
专利说明书EP 0534 859中描述了用于合成伊伐布雷定及其盐酸盐的方法。然而,该对比文献中未特别详述用于以可再现方式获得表现出那些特征的伊伐布雷定形式的条件。
本申请人目前已经发现,可以获得伊伐布雷定的特定盐即盐酸盐的一种晶体形式,该晶形得到充分定义并且表现出有价值的稳定性和加工性能的特征。
更具体而言,本发明涉及盐酸伊伐布雷定的βd-晶形,其特征在于如下粉末X射线衍射图,所述衍射图使用PANalytical X’Pert Pro衍射仪与X’Celerator检测器测定,并根据谱线(ray)位置(布拉格角2θ,以度表示)、谱线高度(以计数表示)、谱线面积(以计数×度表示)、半高处的谱线宽度(“FWHM”,以度表示)和晶面间距d(以_表示)表示:
谱线号 | 2θ角(度) | 高(计数) | 面积(计数×度) | FWHM(度) | 晶面间距(_) |
1 | 4.0 | 244 | 80 | 0.3346 | 22.139 |
2 | 5.9 | 377 | 56 | 0.1506 | 14.829 |
3 | 6.9 | 94 | 50 | 0.5353 | 12.835 |
4 | 9.2 | 1975 | 293 | 0.1506 | 9.623 |
5 | 11.8 | 136 | 27 | 0.2007 | 7.473 |
6 | 12.5 | 1826 | 241 | 0.1338 | 7.083 |
7 | 13.6 | 1834 | 303 | 0.1673 | 6.491 |
8 | 14.5 | 51 | 20 | 0.4015 | 6.119 |
9 | 16.0 | 1441 | 214 | 0.1506 | 5.525 |
10 | 17.3 | 4472 | 738 | 0.1673 | 5.134 |
11 | 18.4 | 546 | 108 | 0.2007 | 4.808 |
12 | 19.6 | 1025 | 169 | 0.1673 | 4.524 |
13 | 20.0 | 688 | 91 | 0.1338 | 4.448 |
14 | 20.4 | 1027 | 186 | 0.184 | 4.362 |
15 | 21.4 | 102 | 24 | 0.2342 | 4.143 |
16 | 22.3 | 1903 | 283 | 0.1506 | 3.990 |
17 | 22.8 | 674 | 89 | 0.1338 | 3.897 |
18 | 23.0 | 623 | 62 | 0.1004 | 3.866 |
19 | 24.4 | 845 | 56 | 0.0669 | 3.647 |
20 | 25.0 | 3749 | 557 | 0.1506 | 3.554 |
21 | 25.5 | 512 | 84 | 0.1673 | 3.497 |
22 | 26.6 | 289 | 76 | 0.2676 | 3.346 |
23 | 28.3 | 275 | 91 | 0.3346 | 3.151 |
24 | 29.1 | 126 | 21 | 0.1673 | 3.066 |
本发明还涉及制备盐酸伊伐布雷定的βd-晶形的方法,该方法的特征在于将盐酸伊伐布雷定和水的混合物或盐酸伊伐布雷定、异丙醇和水的混合物加热,直至溶解完全,然后逐步冷却,直至结晶完全,并且收集由此形成的晶体并脱水。
·在本发明的结晶方法中,能够使用通过任意方法获得的盐酸伊伐布雷定,例如通过专利说明书EP 0534 859中所述的制备方法获得的盐酸伊伐布雷定。
·可以在冷却步骤中有利地将该溶液种晶。
本发明还涉及药物组合物,包含作为活性成分的盐酸伊伐布雷定的βd-晶形以及一种或多种适宜的惰性无毒性赋形剂。在本发明的药物组合物中,更尤其可以提及的是适合于口服、胃肠外(静脉内或皮下)或鼻部给药的那些片剂或糖衣丸、舌下片、明胶胶囊、锭剂、栓剂、霜剂、软膏剂、皮肤凝胶、可注射制剂、可饮用的混悬液。
有用的剂量可以根据疾病的性质和严重程度、给药途径和患者的年龄和体重而改变。该剂量在1-500mg/天之间改变,分一次或多次给药。
下列实施例解释本发明。
在下列实验条件下测定X射线粉末衍射光谱:
-PANalytical X’Pert Pro衍射仪、X’Celerator检测器、温控室;
-电压45kV,电流40mA;
-上机(mounting)θ-θ;
-镍(Kβ)滤波器;
-入射线和衍射线索勒缝隙:0.04拉德;
-发散狭缝的固定角:1/8°;
-障板(mask):10mm;
-防散射狭缝:1/4°;
-测定方式:从3°连续至30°,按0.017°递增;
-测定时间/步骤:19.7s;
-总时间:4min 32s
-测定速度:0.108°/s;
-测定温度:环境。
实施例1:盐酸伊伐布雷定的βd-晶形
将720ml纯化水预加热至50℃,然后分批加入按照专利说明书EP 0534859中所述方法获得的250g盐酸伊伐布雷定,同时搅拌,并且将该混合物在74℃加热,直至溶解完全。将所得澄清溶液在74℃再加热2小时,然后逐步冷却,首先冷却至40℃,然后冷却至环境温度。随后将该溶液在环境温度下贮存2天,然后使固体混悬液在结晶板上以薄层展开。在适度氮气流中驱散过量的水。
通过以5℃/分钟的速率逐步加热至达80℃的温度,使由此获得的产物脱水。
X射线粉末衍射图:
通过下表中整理的重要谱线,给出了盐酸伊伐布雷定βd-晶形的X射线粉末衍射图谱(衍射角):
谱线号 | 2θ角(度) | 高(计数) | 面积(计数×度) | FWHM(度) | 晶面间距(_) |
1 | 4.0 | 244 | 80 | 0.3346 | 22.139 |
2 | 5.9 | 377 | 56 | 0.1506 | 14.829 |
3 | 6.9 | 94 | 50 | 0.5353 | 12.835 |
4 | 9.2 | 1975 | 293 | 0.1506 | 9.623 |
5 | 11.8 | 136 | 27 | 0.2007 | 7.473 |
6 | 12.5 | 1826 | 241 | 0.1338 | 7.083 |
7 | 13.6 | 1834 | 303 | 0.1673 | 6.491 |
8 | 14.5 | 51 | 20 | 0.4015 | 6.119 |
9 | 16.0 | 1441 | 214 | 0.1506 | 5.525 |
10 | 17.3 | 4472 | 738 | 0.1673 | 5.134 |
11 | 18.4 | 546 | 108 | 0.2007 | 4.808 |
12 | 19.6 | 1025 | 169 | 0.1673 | 4.524 |
13 | 20.0 | 688 | 91 | 0.1338 | 4.448 |
14 | 20.4 | 1027 | 186 | 0.184 | 4.362 |
15 | 21.4 | 102 | 24 | 0.2342 | 4.143 |
16 | 22.3 | 1903 | 283 | 0.1506 | 3.990 |
17 | 22.8 | 674 | 89 | 0.1338 | 3.897 |
18 | 23.0 | 623 | 62 | 0.1004 | 3.866 |
19 | 24.4 | 845 | 56 | 0.0669 | 3.647 |
20 | 25.0 | 3749 | 557 | 0.1506 | 3.554 |
21 | 25.5 | 512 | 84 | 0.1673 | 3.497 |
22 | 26.6 | 289 | 76 | 0.2676 | 3.346 |
23 | 28.3 | 275 | 91 | 0.3346 | 3.151 |
24 | 29.1 | 126 | 21 | 0.1673 | 3.066 |
实施例2:药物组合物
制备1000片各自含有5mg伊伐布雷定碱的片剂的配方:
实施例1的化合物 5.39g
玉米淀粉 20g
无水胶体二氧化硅 0.2g
甘露糖醇 63.91g
PVP 10g
硬脂酸镁 0.5g。
Claims (6)
1.通式(I)的盐酸伊伐布雷定的βd-晶形:
其特征在于如下粉末X射线衍射图,所述衍射图使用PANalytical X’PertPro衍射仪与X’Celerator检测器测定,并根据谱线位置(布拉格角2θ,以度表示)、谱线高度(以计数表示)、谱线面积(以计数×度表示)、半高处的谱线宽度(“FWHM”,以度表示)和晶面间距d(以_表示)表示: 谱线号
2θ角(度)
高(计数)
面积(计数×度)
FWHM(度)
晶面间距(_)
1
4.0
244
80
0.3346
22.139
2
5.9
377
56
0.1506
14.829
3
6.9
94
50
0.5353
12.835
4
9.2
1975
293
0.1506
9.623
5
11.8
136
27
0.2007
7.473
6
12.5
1826
241
0.1338
7.083
7
13.6
1834
303
0.1673
6.491
8
14.5
51
20
0.4015
6.119
9
16.0
1441
214
0.1506
5.525
10
17.3
4472
738
0.1673
5.134
11
18.4
546
108
0.2007
4.808
12
19.6
1025
169
0.1673
4.524
13
20.0
688
91
0.1338
4.448
14
20.4
1027
186
0.184
4.362
15
21.4
102
24
0.2342
4.143
16
22.3
1903
283
0.1506
3.990
17
22.8
674
89
0.1338
3.897
18
23.0
623
62
0.1004
3.866
19
24.4
845
56
0.0669
3.647
20
25.0
3749
557
0.1506
3.554
21
25.5
512
84
0.1673
3.497
22
26.6
289
76
0.2676
3.346
23
28.3
275
91
0.3346
3.151
24
29.1
126
21
0.1673
3.066
2.制备根据权利要求1的盐酸伊伐布雷定的βd-晶形的方法,其特征在于将盐酸伊伐布雷定和水的混合物或盐酸伊伐布雷定、异丙醇和水的混合物加热,直至溶解完全,然后逐步冷却,直至结晶完全,并且收集由此形成的晶体,然后脱水。
3.根据权利要求2的方法,其特征在于在冷却步骤中将盐酸伊伐布雷定的溶液种晶。
4.药物组合物,包含作为活性成分的根据权利要求1的盐酸伊伐布雷定的βd-晶形以及一种或多种药学上可接受的惰性无毒性载体。
5.根据权利要求1的盐酸伊伐布雷定的βd-晶形在制备可用作减慢心率药的药物中的用途。
6.根据权利要求1的盐酸伊伐布雷定的βd-晶形在制备药物中的用途,所述药物可用于治疗或预防心肌缺血的各种临床情况如心绞痛、心肌梗死和相关节律失常,以及涉及节律失常的各种病理情况、尤其是室上性节律失常,和心力衰竭。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0501987 | 2005-02-28 | ||
FR0501987A FR2882554B1 (fr) | 2005-02-28 | 2005-02-28 | Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1827599A true CN1827599A (zh) | 2006-09-06 |
CN100404512C CN100404512C (zh) | 2008-07-23 |
Family
ID=34954878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100580746A Active CN100404512C (zh) | 2005-02-28 | 2006-02-28 | 盐酸伊伐布雷定的βd-晶形、其制备方法和含有它的药物组合物 |
Country Status (41)
Country | Link |
---|---|
US (3) | US7361652B2 (zh) |
EP (1) | EP1695710B1 (zh) |
JP (1) | JP4628973B2 (zh) |
KR (1) | KR100835446B1 (zh) |
CN (1) | CN100404512C (zh) |
AP (1) | AP2190A (zh) |
AR (1) | AR052925A1 (zh) |
AT (1) | ATE397449T1 (zh) |
BR (1) | BRPI0600795B8 (zh) |
CA (1) | CA2537420C (zh) |
CO (1) | CO5770098A1 (zh) |
CR (1) | CR8247A (zh) |
CY (1) | CY1109011T1 (zh) |
DE (1) | DE602006001365D1 (zh) |
DK (1) | DK1695710T3 (zh) |
EA (1) | EA008466B1 (zh) |
EC (1) | ECSP066374A (zh) |
ES (1) | ES2308690T3 (zh) |
FR (1) | FR2882554B1 (zh) |
GE (1) | GEP20084466B (zh) |
GT (1) | GT200600085A (zh) |
HK (1) | HK1096388A1 (zh) |
HR (1) | HRP20080418T5 (zh) |
IL (1) | IL173958A0 (zh) |
JO (1) | JO2516B1 (zh) |
MA (1) | MA28133A1 (zh) |
MY (1) | MY158127A (zh) |
NO (1) | NO338369B1 (zh) |
NZ (1) | NZ545577A (zh) |
PE (1) | PE20061091A1 (zh) |
PL (1) | PL1695710T3 (zh) |
PT (1) | PT1695710E (zh) |
RS (1) | RS50599B (zh) |
SA (1) | SA06270039B1 (zh) |
SG (1) | SG125230A1 (zh) |
SI (1) | SI1695710T1 (zh) |
TW (1) | TWI315306B (zh) |
UA (1) | UA80903C2 (zh) |
UY (1) | UY29404A1 (zh) |
WO (1) | WO2006092491A1 (zh) |
ZA (1) | ZA200601761B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010081342A1 (zh) | 2009-01-13 | 2010-07-22 | 江苏恒瑞医药股份有限公司 | 硫酸伊伐布雷定及其i型结晶的制备方法 |
CN101353325B (zh) * | 2007-07-27 | 2011-11-09 | 上海优拓医药科技有限公司 | 稳定型盐酸伊伐布雷定结晶及其制备方法 |
CN107056706A (zh) * | 2015-12-21 | 2017-08-18 | 江苏恒瑞医药股份有限公司 | 一种用于制备盐酸伊伐布雷定α晶型的方法 |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004294259C1 (en) * | 2003-12-04 | 2014-07-10 | Bayer Cropscience Aktiengesellschaft | Active substance combination having insecticidal and acaricidal properties |
FR2868777B1 (fr) * | 2004-04-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
FR2882554B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2882555B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2882553B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2882556B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2891827B1 (fr) * | 2005-10-11 | 2007-12-28 | Servier Lab | Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2891826B1 (fr) * | 2005-10-11 | 2007-12-28 | Servier Lab | Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
FR2894825B1 (fr) * | 2005-12-21 | 2010-12-03 | Servier Lab | Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent |
ES2381771T3 (es) | 2006-11-30 | 2012-05-31 | Cadila Healthcare Limited | Procedimiento para la preparación de hidrocloruro de ivabradina |
KR101478855B1 (ko) | 2007-05-30 | 2015-01-02 | 인드-스위프트 래버러토리즈 리미티드 | 이바브라딘 히드로클로라이드 및 그의 다형태의 제조방법 |
FR2920773B1 (fr) * | 2007-09-11 | 2009-10-23 | Servier Lab | Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
CN102264689B (zh) | 2008-12-22 | 2014-12-31 | 新梅斯托克尔卡公司 | 制备伊伐布雷定的方法 |
SI23290A (sl) | 2010-02-12 | 2011-08-31 | Krka D.D., Novo Mesto | Nove oblike ivabradin hidroklorida |
HUP1000245A2 (en) | 2010-05-07 | 2011-11-28 | Richter Gedeon Nyrt | Industrial process for the production ivabradin salts |
CA2800442C (en) | 2010-06-14 | 2018-05-22 | Ratiopharm Gmbh | Ivabradine-containing pharmaceutical composition with modified release |
WO2012025940A1 (en) | 2010-08-25 | 2012-03-01 | Cadila Healthcare Limited | Polymorphic form of ivabradine hydrochloride and process for preparation thereof |
WO2013017582A1 (en) | 2011-08-02 | 2013-02-07 | Sandoz Ag | Acetone solvate of ivabradine hydrochloride |
EP2589594A1 (en) | 2011-11-04 | 2013-05-08 | Urquima S.A. | Ivabradine hydrochloride Form IV |
EP2773621B1 (en) | 2011-11-04 | 2015-12-30 | Synthon BV | A process for making crystalline delta-form of ivabradine hydrochloride |
US9120755B2 (en) | 2011-11-14 | 2015-09-01 | Cadila Healthcare Limited | Polymorphic forms of ivabradine hydrochloride |
WO2014114341A1 (en) | 2013-01-24 | 2014-07-31 | Synthon Bv | Process for making ivabradine |
CZ2013767A3 (cs) | 2013-10-02 | 2015-04-29 | Zentiva, K.S. | Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice |
WO2015001133A1 (en) | 2013-12-12 | 2015-01-08 | Synthon B.V. | Pharmaceutical composition comprising amorphous ivabradine |
ES2717715T3 (es) | 2014-02-14 | 2019-06-24 | Synthon Bv | Composición farmacéutica que comprende polimorfo IV de clorhidrato de ivabradina |
CZ305436B6 (cs) | 2014-07-10 | 2015-09-16 | Zentiva, K.S. | Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice |
EP3366282A1 (en) | 2017-02-28 | 2018-08-29 | Sanovel Ilac Sanayi ve Ticaret A.S. | Solid oral pharmaceutical compositions of ivabradine |
TR201703066A2 (tr) | 2017-02-28 | 2018-09-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari |
JP7132757B2 (ja) | 2018-06-12 | 2022-09-07 | プレス工業株式会社 | スライド窓保持装置 |
IT202000025312A1 (it) | 2020-10-26 | 2022-04-26 | Cambrex Profarmaco Milano S R L | Processi per la preparazione di polimorfi di ivabradina hcl |
IT202100019988A1 (it) | 2021-07-27 | 2023-01-27 | Campagnolo Srl | Dispositivo manuale di comando per bicicletta |
IT202100019967A1 (it) | 2021-07-27 | 2023-01-27 | Campagnolo Srl | Dispositivo manuale di comando per bicicletta |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3119874A1 (de) * | 1981-05-19 | 1982-12-09 | Dr. Karl Thomae Gmbh, 7950 Biberach | "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel" |
DE3418270A1 (de) * | 1984-05-17 | 1985-11-21 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue aminotetralinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
FR2681862B1 (fr) * | 1991-09-27 | 1993-11-12 | Adir Cie | Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent. |
FR2868777B1 (fr) * | 2004-04-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
FR2882555B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2882554B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2882553B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2882556B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2891827B1 (fr) * | 2005-10-11 | 2007-12-28 | Servier Lab | Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2891826B1 (fr) * | 2005-10-11 | 2007-12-28 | Servier Lab | Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
-
2005
- 2005-02-28 FR FR0501987A patent/FR2882554B1/fr not_active Expired - Fee Related
-
2006
- 2006-02-13 MA MA28794A patent/MA28133A1/fr unknown
- 2006-02-14 PE PE2006000168A patent/PE20061091A1/es not_active Application Discontinuation
- 2006-02-14 JO JO200649A patent/JO2516B1/en active
- 2006-02-15 EC EC2006006374A patent/ECSP066374A/es unknown
- 2006-02-21 CR CR8247A patent/CR8247A/es not_active Application Discontinuation
- 2006-02-21 SG SG200601142A patent/SG125230A1/en unknown
- 2006-02-22 US US11/359,263 patent/US7361652B2/en active Active
- 2006-02-22 GT GT200600085A patent/GT200600085A/es unknown
- 2006-02-22 TW TW095105988A patent/TWI315306B/zh active
- 2006-02-22 AP AP2006003520A patent/AP2190A/xx active
- 2006-02-24 UY UY29404A patent/UY29404A1/es not_active Application Discontinuation
- 2006-02-24 CA CA2537420A patent/CA2537420C/fr active Active
- 2006-02-24 BR BRPI0600795A patent/BRPI0600795B8/pt active IP Right Grant
- 2006-02-27 IL IL173958A patent/IL173958A0/en active IP Right Grant
- 2006-02-27 NO NO20060947A patent/NO338369B1/no unknown
- 2006-02-27 EA EA200600321A patent/EA008466B1/ru unknown
- 2006-02-27 NZ NZ545577A patent/NZ545577A/en unknown
- 2006-02-27 KR KR1020060018721A patent/KR100835446B1/ko active IP Right Grant
- 2006-02-27 SA SA06270039A patent/SA06270039B1/ar unknown
- 2006-02-27 UA UAA200602128A patent/UA80903C2/uk unknown
- 2006-02-27 GE GEAP20069264A patent/GEP20084466B/en unknown
- 2006-02-27 MY MYPI20060820A patent/MY158127A/en unknown
- 2006-02-28 DE DE602006001365T patent/DE602006001365D1/de active Active
- 2006-02-28 EP EP06290329A patent/EP1695710B1/fr active Active
- 2006-02-28 CN CNB2006100580746A patent/CN100404512C/zh active Active
- 2006-02-28 WO PCT/FR2006/000442 patent/WO2006092491A1/fr not_active Application Discontinuation
- 2006-02-28 PL PL06290329T patent/PL1695710T3/pl unknown
- 2006-02-28 DK DK06290329T patent/DK1695710T3/da active
- 2006-02-28 SI SI200630046T patent/SI1695710T1/sl unknown
- 2006-02-28 JP JP2006051648A patent/JP4628973B2/ja active Active
- 2006-02-28 AT AT06290329T patent/ATE397449T1/de active
- 2006-02-28 ZA ZA2006/01761A patent/ZA200601761B/en unknown
- 2006-02-28 AR ARP060100729A patent/AR052925A1/es not_active Application Discontinuation
- 2006-02-28 PT PT06290329T patent/PT1695710E/pt unknown
- 2006-02-28 RS RSP-2008/0366A patent/RS50599B/sr unknown
- 2006-02-28 ES ES06290329T patent/ES2308690T3/es active Active
- 2006-02-28 CO CO06019935A patent/CO5770098A1/es not_active Application Discontinuation
-
2007
- 2007-02-01 HK HK07101191A patent/HK1096388A1/xx unknown
-
2008
- 2008-02-27 US US12/072,577 patent/US20080161286A1/en not_active Abandoned
- 2008-07-18 CY CY20081100750T patent/CY1109011T1/el unknown
- 2008-08-27 HR HR20080418T patent/HRP20080418T5/xx unknown
-
2009
- 2009-08-27 US US12/583,857 patent/US7867995B2/en active Active
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101353325B (zh) * | 2007-07-27 | 2011-11-09 | 上海优拓医药科技有限公司 | 稳定型盐酸伊伐布雷定结晶及其制备方法 |
WO2010081342A1 (zh) | 2009-01-13 | 2010-07-22 | 江苏恒瑞医药股份有限公司 | 硫酸伊伐布雷定及其i型结晶的制备方法 |
CN107056706A (zh) * | 2015-12-21 | 2017-08-18 | 江苏恒瑞医药股份有限公司 | 一种用于制备盐酸伊伐布雷定α晶型的方法 |
CN107056706B (zh) * | 2015-12-21 | 2020-05-05 | 江苏恒瑞医药股份有限公司 | 一种用于制备盐酸伊伐布雷定α晶型的方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1827599A (zh) | 盐酸伊伐布雷定的βd-晶形、其制备方法和含有它的药物组合物 | |
CN1827600A (zh) | 盐酸伊伐布雷定的β-晶形、其制备方法和含有它的药物组合物 | |
CN1827601A (zh) | 盐酸伊伐布雷定的γd-晶形、其制备方法和含有它的药物组合物 | |
CN1827602A (zh) | 盐酸伊伐布雷定的γ-晶形、其制备方法和含有它的药物组合物 | |
CN1948292A (zh) | δ-结晶形式的盐酸伊伐布雷定,其制备方法以及包含它的药物组合物 | |
CN1948293A (zh) | δd-结晶形式的盐酸伊伐布雷定,其制备方法以及包含它的药物组合物 | |
MXPA06002274A (en) | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | |
MXPA06002277A (en) | Beta d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | |
MXPA06002275A (en) | Gamma-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1096388 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1096388 Country of ref document: HK |